Clinical Trials
12 trialsNCT00365105 2024-09-20
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00079001 2020-05-12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00987636 2019-10-22
EWING2008
University Hospital Muenster
Phase 3 Completed
NCT00130494 2019-04-16
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
Spanish Breast Cancer Research Group
Phase 3 Terminated
NCT00099177 2017-08-16
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Hoffmann-La Roche
Phase 3 Terminated
NCT00099203 2017-08-16
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Hoffmann-La Roche
Phase 3 Terminated
NCT00685646 2015-10-16
ZAPCA
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 3 Completed
NCT00301886 2013-11-13
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
SWOG Cancer Research Network
Phase 3 Withdrawn
NCT00072020 2013-08-02
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00326820 2013-03-13
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
Wales Cancer Trials Unit
Phase 3 Unknown
NCT00003884 2013-02-21
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Novartis
Phase 3 Completed